the alzheimer’s drug discovery foundation (addf) and harrington discovery institute have partnered to form the addf-harrington scholar program. this program recognizes physicians or scientists across the us and canada, who are doing research to develop drugs to prevent, treat and cure alzheimer’s disease. the award provides funding and drug development support to help bridge the gap between basic discovery and the clinical realm.

up to three addf-harrington scholar awards are made each year through a competitive selection process.

the fy20 defense appropriation provides $15 million (m) to the department of defense autism research program (arp) to provide support for research of exceptional scientific merit and innovation with high impact that focuses on autism spectrum disorders (asd).  as directed by the office of the assistant secretary of defense for health affairs, the defense health agency j9, research and development directorate, manages the defense health program’s research, development, test, and evaluation (rdt&e) appropriation.  the managing agent for the anticipated program announcements/funding opportunities is the congressionally directed medical research programs (cdmrp) at the u.s. army medical research and development command (usamrdc).

fy20 arp program announcements and general application instructions for the following award mechanisms are posted on the grants.gov website. 

https://cdmrp.army.mil/funding/arp

clinical trial award – preapplication due april 28, 2020

investigators at or above the level of assistant professor (or equivalent), or

early-career investigator partnering principal investigator (pi) option: investigators at or above the level of assistant professor (or equivalent) may collaborate on a single application with a young investigator (at the level of postdoctoral fellow up to early-career independent faculty) who meets the following criteria at the application submission deadline date:

• must be in a current postdoctoral training position or have completed postdoctoral training by the application deadline
• is no more than 7 years from the receipt of a terminal degree

• has the freedom to commit at least 50% time to the project

supports research with the potential to have a major impact on the treatment and/or management of asd.

applications in the following areas are strongly encouraged:

• dissemination/implementation of clinically validated interventions
• behavioral, cognitive, and other non-pharmacological therapies for asd core symptoms or to alleviate co-occurring conditions.
• pharmacological, genetic, and other biological treatments for asd core symptoms or to alleviate co-occurring conditions.
• improve diagnosis and access to services across the life span
• interventions promoting success in key transitions to adulthood for individuals living with asd
• healthcare provider-focused training or tools to improve healthcare delivery for individuals with asd across the life span and the continuum of care (i.e., primary care, urgent/emergent care, and disaster relief)
• cultural, socioeconomic, and gender factors in diagnosis, treatment efficacy, delivery, and access to services
• understanding heterogeneity in treatment response

preliminary data relevant to the proposed clinical trial are required.

pre-application is required; application submission is by invitation only.

early-career investigator partnering pi option supports the development of young investigators pursuing or wishing to pursue a career in asd clinical trial research.

the maximum allowable funding for the entire period of performance is $2,000,000 in direct costs (plus indirect costs).

maximum period of performance is 4 years.

early-career investigator partnering pi option:

the maximum allowable funding for the entire period of performance is $2,300,000 for direct costs (plus indirect costs).

maximum period of performance is 4 years.

clinical translational research award – preapplication due april 28, 2020

investigators at or above the level of assistant professor (or equivalent)

• supports early-phase, proof-of-principle translational studies with the potential to have a major impact on the treatment and/or management of asd.
• applications in the following areas are strongly encouraged:

• dissemination/implementation of clinically validated interventions
• behavioral, cognitive, and other non-pharmacological therapies for asd core symptoms or to alleviate co-occurring conditions.
• pharmacological, genetic, and other biological treatments for asd core symptoms or to alleviate co-occurring conditions.
• improve diagnosis and access to services across the life span
• interventions promoting success in key transitions to adulthood for individuals living with asd
• healthcare provider-focused training or tools to improve healthcare delivery for individuals with asd across the life span and the continuum of care (i.e., primary care, urgent/emergent care, and disaster relief)
• cultural, socioeconomic, and gender factors in diagnosis, treatment efficacy, delivery, and access to services
• understanding heterogeneity in treatment response
• pre-application is required; application submission is by invitation only.
• maximum period of performance is 3 years.

• preliminary data relevant to the proposed project are required.

• the maximum allowable funding for the entire period of performance is $600,000 in direct costs (plus indirect costs).

idea development award – preapplication due april 28, 2020

investigators at or above the level of assistant professor (or equivalent)

multiple pi option:   up to two investigators may collaborate on a single application, each of whom will be recognized as a pi and receive a separate award. 

• supports the development of innovative, high-impact ideas that advance the understanding of asd and ultimately lead to improved outcomes.
• applications in the following areas are strongly encouraged:
  • test of implementation strategies to increases use of evidence-based practices
  • development of healthcare provider-focused training or tools to improve healthcare delivery for individuals with asd across the life span and the continuum of care (i.e., primary care, urgent/emergent care, and disaster relief)
  • assessment of novel therapeutics using valid preclinical models
  • mechanisms of heterogeneous clinical expression of asd
  • environmental risk factors
  • improve diagnosis across the life span
  • factors promoting success in key transitions to independence for individuals living with asd
  • cultural and socioeconomic factors in treatment efficacy, delivery, and access to services
  • mechanisms underlying sex differences in asd diagnosis
  • mechanisms underlying conditions co-occurring with asd (e.g., sleep disturbances, gastrointestinal issues, inflammation, aggression, depression, anxiety, attention deficit, seizures)
  • factors impacting quality of life during geographic relocation, such as military permanent change of station
  • long-term treatment outcomes from previous clinical trials for asd core symptoms or to alleviate co-occurring conditions
• preliminary data are required.
• multiple pi option: up to two investigators may collaborate on a single application, each of whom will be recognized as a pi and receive a separate award.
• pre-application is required; application submission is by invitation only.

• the maximum allowable funding for the entire period of performance is $550,000 in direct costs (plus indirect costs).

• maximum period of performance is 3 years.

a pre-application is required and must be submitted through the electronic biomedical research application portal (ebrap) at https://ebrap.org prior to the pre-application deadline.  all applications must conform to the final program announcements and general application instructions available for electronic downloading from the grants.gov website.  the application package containing the required forms for each award mechanism will also be found on grants.gov.  a listing of all cdmrp and other usamrdc extramural funding opportunities can be obtained on the grants.gov website by performing a basic search using cfda number 12.420. 

for email notification when program announcements are released, subscribe to program-specific news and updates under “email subscriptions” on the ebrap homepage at https://ebrap.org.  for more information about the arp or other cdmrp-administered programs, please visit the cdmrp website (https://cdmrp.army.mil).

point of contact:

cdmrp help desk 
301-682-5507 
help@ebrap.org

description: fund canadian-led network(s) to plan and implement activities related to connecting and bridging partnerships, enabling global access of amr related tools and knowledge, facilitating data sharing and supporting capacity building leading to awareness and scientific innovation.
funding: $604k cihr-iii and cihr-ipph, over 3 years
deadline: april 2020 (full proposal)

the canadian cancer society (ccs) is issuing a special call for grant applications focused on rare and aggressive uterine cancers, with an emphasis on uterine carcinosarcoma in particular. as a result of a generous donation, there is funding available to support one meritorious application that will impact our understanding of uterine carcinosarcoma and other aggressive uterine cancers, particularly as it relates to the prevention, early detection, diagnosis, and/or treatment of these hard-to-treat cancers. 

eligible types of uterine cancer include:

•   uterine carcinosarcoma
•   serous carcinoma
•   uterine leiomyosarcoma
•   uterine clear cell carcinoma
•   endometrial stromal sarcoma (high-grade)
•   undifferentiated sarcomas

 enable scientists in cardiovascular research from different countries to come together and build effective collaborations on a common interdisciplinary research project based on complementarities and sharing of expertise with a clear translation research approach for future clinical impact.

call for applications information and application form to apply to the law foundation of ontario’s responsive grants program
deadlines: small & major grant – march 31; small grant – september 1 (every year)
grant amounts: small grant – up to $15k; major grant – up to $100,000 and $100k to $250k

the fy20 defense appropriations act providing funding to the department of defense alsrp to support innovative and impactful research to develop new treatments for als.  as directed by the office of the assistant secretary of defense for health affairs, the defense health agency j9, research and development directorate manages the defense health program (dhp) research, development, test, and evaluation (rdt&e) appropriation.  the managing agent for the anticipated program announcements/funding opportunities is the congressionally directed medical research programs (cdmrp) at the u.s. army medical research and development command (usamrdc).

fy20 alsrp program announcements and general application instructions for the following award mechanisms are posted on the grants.gov website.    

https://cdmrp.army.mil/funding/alsrp

therapeutic development award - pre-application april 15, 2020

independent investigators at all academic levels (or equivalent)

• pre-application is required; full application submission is by invitation only.
• supports preclinical secondary validation and ind-enabling studies of therapeutics for als.
• preliminary data is required, including efficacy in at least one als-relevant model system with a lead molecule/class of compounds.
• biomarker development and/or characterization (if not already validated), in parallel to the main therapeutic effort, is a critical component of the tda proposal.
• maximum funding of $1,000,000 for direct costs plus indirect costs
• maximum period of performance is 3 years

therapeutic idea award - pre-application april 15, 2020

independent investigators at all academic levels (or equivalent)

• pre-application is required; full application submission is by invitation only.
• supports hypothesis-driven preclinical therapeutic development.
• preliminary data are not required.
• projects focusing primarily on investigating als pathophysiology are outside the scope of this award mechanism.
• early career investigators are encouraged to apply.
• therapeutic relevant biomarker option: applications which include the development of biomarkers in parallel with the main therapeutic advancement effort, and that meet the criteria outlined in the funding opportunity announcement, will qualify for a higher level of funding.
• maximum funding of $500,000 for direct costs plus indirect costs
• maximum funding of $600,000 for direct costs plus indirect costs if applying for the therapeutic relevant biomarker option
• maximum period of performance is 2 years

new for fy20! clinical development award - pre-application april 15, 2020

independent investigators at all academic levels (or equivalent) 

• pre-application is required; full application submission is by invitation only.
• supports leveraging of human-based als resources through correlative clinical research.
• early career investigators and/or early career physician scientists are encouraged to apply.
• types of efforts that will be supported include:

o  using human subject-based resources to better define subtypes, predict therapeutic response, or assess prognosis

o  correlating clinical trial-related biosamples, imaging, or epidemiological data with clinical outcomes

o  adding a secondary aim/goal to an anticipated/ongoing clinical trial, not otherwise supported by the trial

o  studies to evaluate optimizing components of current als clinical care

• maximum funding of $300,000 for direct costs plus indirect costs
• maximum period of performance is 2 years

a pre-application is required and must be submitted through the electronic biomedical research application portal (ebrap) at https://ebrap.org prior to the pre-application deadline.  all applications must conform to the final program announcements and general application instructions available for electronic downloading from the grants.gov website.  the application package containing the required forms for each award mechanism will also be found on grants.gov.  a listing of all cdmrp and other usamrdc extramural funding opportunities can be obtained on the grants.gov website by performing a basic search using cfda number 12.420.  

for email notification when program announcements are released, subscribe to program-specific news and updates under “email subscriptions” on the ebrap homepage at https://ebrap.org.  for more information about the alsrp or other cdmrp-administered programs, please visit the cdmrp website (https://cdmrp.army.mil).

point of contact:

cdmrp help desk 
301-682-5507 
help@ebrap.org

the namesake grant program was developed in 2016 to interconnect communities within canada and is administered by the canadian foundation for women's health (cfwh). these grants allow for local businesses and interested persons to offer support to meaningful research topics within women’s health.

the namesake grant program was developed in 2016 to interconnect communities within canada and is administered by the canadian foundation for women's health (cfwh). these grants allow for local businesses and interested persons to offer support to meaningful research topics within women’s health.